Varicella in immunocompetent children in the first two years of life: role of treatment with oral acyclovir. Italian Acyclovir-Chickenpox Study Group.
An open multicenter study has been carried out to evaluate efficacy and tolerability of oral acyclovir in the treatment of varicella in immunocompetent patients in the first two years of life. Fifty-three children aged 3-24 months received acyclovir at 80 mg/Kg/day in four divided doses for 4 to 6 days; 24 of them were treated in the first 24 hours following disease onset, while the remaining 29 patients were enrolled within 48 hours. The assessment of evolution of disease signs and symptoms showed a rapid resolution of fever, itching and other constitutional symptoms, with interruption of vesicle formation and acceleration of cutaneous healing processes. No statistically significant differences have been demonstrated as to disease progression between patients treated in the first 24 hours, when compared with subjects receiving acyclovir in the following 24 hours. Acyclovir confirmed its excellent clinical and laboratory safety profile. By acting favorably on both the duration and severity of disease signs and symptoms, acyclovir treatment should be recommended in young children and infants with varicella, since a higher incidence of severe and complicated disease has been observed in these patient groups.
Chiodo
F
F
Istituto Malattie Infettive, Università di Bologna, Italy.
Manfredi
R
R
Antonelli
P
P
Caramia
G
G
Carnelli
V
V
Catania
S
S
Ceccarelli
M
M
De Santis
U
U
Ghirardini
G
G
Loizzo
B
B
D000212:Acyclovir / Q000008:administration & dosage* / Q000009:adverse effects; D000284:Administration, Oral; D002644:Chickenpox / Q000188:drug therapy* / Q000276:immunology*; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007121:Immunocompetence; D007223:Infant; D008297:Male; D013535:Suspensions; D016896:Treatment Outcome
D013535:Suspensions; D000212:Acyclovir